uniQure N.V. (QURE)

uniQure's stock experienced significant events in the past six months. On November 3, 2025, the stock plummeted after the FDA questioned the adequacy of AMT-130 data for BLA submission. On March 2, 2026, the stock plunged following the 2025 financial results and a regulatory update for AMT-130, where the FDA recommended a Phase III study. From March 5-10, 2026, public criticism from federal health officials regarding AMT-130 data further impacted the stock, leading to a lawsuit. In April 2026, positive news from a meeting with the UK's MHRA for AMT-130 led to a stock price increase. On May 5, 2026, Q1 2026 earnings beat EPS estimates but missed on revenue, with updates on pipeline programs, including a scheduled Type B FDA meeting for AMT-130, ongoing progress for AMT-260 and AMT-191, and the discontinuation of AMT-162, causing the stock to surge.

Information regarding specific demand seasonality for uniQure N.V.'s products and services was not found. The demand for its products is primarily driven by medical need and regulatory approvals rather than typical seasonal consumer patterns.

uniQure N.V. is a Dutch biopharmaceutical company focused on developing gene therapies for genetic and other devastating diseases, operating within the Biotechnology & Drugs industry. Their major product is HEMGENIX, a gene therapy for hemophilia B, for which uniQure licensed global commercialization rights to CSL Behring. The company's pipeline includes AMT-130 for Huntington's disease, AMT-260 for refractory mesial temporal lobe epilepsy, AMT-191 for Fabry disease, and the discontinued AMT-162 for SOD1 amyotrophic lateral sclerosis (ALS).

uniQure N.V. is headquartered in Amsterdam, the Netherlands, and maintains a presence in Lexington, Massachusetts (USA), and Basel (Switzerland). The company aims to expand its global market presence in North America, Europe, and Asia.

uniQure's brand reputation has been significantly impacted, particularly by events related to AMT-130. The company faced public criticism from federal health officials, including a senior FDA official, who accused uniQure of presenting distorted and manipulated clinical data for AMT-130. These allegations followed the FDA's earlier reversal regarding the sufficiency of AMT-130's Phase I/II data for accelerated approval, leading to a securities class action lawsuit.

uniQure N.V. has a diverse ownership structure, with institutional investors holding approximately 18.88% to 25.50% of the shares, insiders owning about 2.53%, and public companies and individual investors holding around 71.97%. Major institutional shareholders include Fmr Llc, Avoro Capital Advisors LLC, Standard Life Aberdeen plc, Rtw Investments, Lp, State Street Corp, Jpmorgan Chase & Co, Susquehanna International Group, Llp, BlackRock, Inc., Two Sigma Investments, Lp, and MPM Oncology Impact Management LP. Recent insider trading activity has shown sales by several executives.